Breaking News Instant updates and real-time market news.

CLVS

Clovis

$35.77

-1.51 (-4.05%)

10:54
10/07/16
10/07
10:54
10/07/16
10:54

Clovis selloff a buying opportunity, says SunTrust

SunTrust analyst Peter Lawson views today's selloff in shares of Clovis Oncology as a buying opportunity, saying today's concern "seems like noise." The analyst has a Buy rating on the stock with a $50 price target. Clovis is down 13%, or $4.64, to $31.13 but is well off the day's lows.

  • 07

    Oct

  • 06

    Nov

  • 23

    Feb

CLVS Clovis
$35.77

-1.51 (-4.05%)

09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.

TODAY'S FREE FLY STORIES

13:05
01/23/18
01/23
13:05
01/23/18
13:05
General news
2-Yr Note Auction Coupon Rate data reported »

2-Yr Note Auction Coupon…

13:05
01/23/18
01/23
13:05
01/23/18
13:05
General news
2-Yr Note Auction Total Amount data reported »

2-Yr Note Auction Total…

OSTK

Overstock.com

$77.40

-0.25 (-0.32%)

13:05
01/23/18
01/23
13:05
01/23/18
13:05
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

13:03
01/23/18
01/23
13:03
01/23/18
13:03
Hot Stocks
Samsung unveils 860 PRO, 860 EVO solid state drives powered by V-NAND »

Samsung Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

CREE

Cree

$36.69

0.4 (1.10%)

12:58
01/23/18
01/23
12:58
01/23/18
12:58
Downgrade
Cree rating change  »

Tigress downgrades Cree…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CREE

Cree

$36.69

0.4 (1.10%)

12:54
01/23/18
01/23
12:54
01/23/18
12:54
Downgrade
Cree rating change  »

Cree downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PUBGY

Publicis

$17.85

0.03 (0.17%)

12:50
01/23/18
01/23
12:50
01/23/18
12:50
Hot Stocks
Publicis says undergoing 'destabilization attempt,' rejects allegations »

Publicis Groupe said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$61.67

0.42 (0.69%)

12:50
01/23/18
01/23
12:50
01/23/18
12:50
Options
Call buyers in Merck as shares move higher »

Call buyers in Merck as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

12:50
01/23/18
01/23
12:50
01/23/18
12:50
General news
U.S. corporate bond update: the slate is thin with just a couple of issues »

U.S. corporate bond…

BCS

Barclays

$11.68

-0.06 (-0.51%)

12:46
01/23/18
01/23
12:46
01/23/18
12:46
Periodicals
Ex-Barclays banker recorded saying he destroyed key report, Bloomberg says »

Former Barclays top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.29

-0.16 (-0.30%)

12:43
01/23/18
01/23
12:43
01/23/18
12:43
Hot Stocks
Verizon giving 50 shares to employees following tax reform »

Verizon Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

12:42
01/23/18
01/23
12:42
01/23/18
12:42
Hot Stocks
Cboe Global Markets recognized in Hong Kong as approved stock exchange »

Cboe Global Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Feb

RIG

Transocean

$11.68

-0.25 (-2.10%)

12:40
01/23/18
01/23
12:40
01/23/18
12:40
Options
Rolling action in Transocean calls »

Rolling action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$6.30

0.01 (0.16%)

, JPM

JPMorgan

$114.46

0.13 (0.11%)

12:35
01/23/18
01/23
12:35
01/23/18
12:35
Hot Stocks
GoPro falls after Morgan Stanley downgrade cites limited strategic value »

Shares of GoPro (GPRO)…

GPRO

GoPro

$6.30

0.01 (0.16%)

JPM

JPMorgan

$114.46

0.13 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MET

MetLife

$53.56

-0.29 (-0.54%)

12:31
01/23/18
01/23
12:31
01/23/18
12:31
Hot Stocks
MetLife issues statement on court decision to dismiss appeal in SIFI litigation »

MetLife chairman,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 12

    Jun

CVE

Cenovus Energy

$10.43

0.04 (0.38%)

12:30
01/23/18
01/23
12:30
01/23/18
12:30
Options
Call buyers in Cenovus Energy as shares tick higher »

Call buyers in Cenovus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$135.52

0.31 (0.23%)

12:28
01/23/18
01/23
12:28
01/23/18
12:28
Technical Analysis
Technical Earnings Preview: United Technologies in uptrend before news »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AGN

Allergan

$187.32

-0.83 (-0.44%)

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Options
Allergan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

12:25
01/23/18
01/23
12:25
01/23/18
12:25
Conference/Events
Leerink healthcare services analysts hold an analyst/industry conference call »

Healthcare Services…

VZ

Verizon

$53.23

-0.235 (-0.44%)

12:22
01/23/18
01/23
12:22
01/23/18
12:22
Periodicals
Verizon giving employees 50 shares of restricted stock, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

CHFN

Charter Financial

$18.13

-0.12 (-0.66%)

12:21
01/23/18
01/23
12:21
01/23/18
12:21
Hot Stocks
Charter Financial raises quarterly dividend to 8c per share from 5c »

Charter Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$36.96

0.7 (1.93%)

, FOXA

21st Century Fox

$37.31

0.66 (1.80%)

12:20
01/23/18
01/23
12:20
01/23/18
12:20
Hot Stocks
21st Century Fox 'welcomes' part of CMA finding, 'disappointed' about plurality »

21st Century Fox (FOXA)…

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

SKYAY

Sky

$55.97

0.72 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 07

    Feb

$NSD

NASDAQ Market Internals

12:17
01/23/18
01/23
12:17
01/23/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Hot Stocks
Netflix's 'Mudbound' gets four Oscar noms, Amazon's 'The Big Sick' gets nod »

Films produced by Netflix…

NFLX

Netflix

$227.58

7.12 (3.23%)

AMZN

Amazon.com

$1,327.31

32.73 (2.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

$NYE

NYSE Market Internals

12:16
01/23/18
01/23
12:16
01/23/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.